Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The page's revision label updated from v3.6.4 to v3.6.5, indicating a minor update to the page revision history.
    Difference
    0.0%
    Check dated 2026-08-11T22:06:11.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Three site entries were edited to standardize their names by removing diacritics and minor punctuation: Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 253147; Hospital Da Crianca Santo Antonio /ID# 233249; and Fundacion Ctic - Centro De Tratamiento E Investigacion Sobre Cancer Luis Carlos /ID# 258131.
    Difference
    0.1%
    Check dated 2026-07-28T19:22:38.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Adds clarifications that Telisotuzumab Vedotin is investigational and outlines a 1:1 randomized design between Telisotuzumab Vedotin and Docetaxel, with about 768 participants across roughly 330 sites worldwide. Updates the study’s locations and related eligibility notes, replacing the prior enrollment figure (698) and adding new sites.
    Difference
    0.7%
    Check dated 2026-07-21T14:00:22.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The revision label changed from v3.6.0 to v3.6.3, signaling a new software release for the page. This is a technical update rather than content changes.
    Difference
    0.0%
    Check dated 2026-06-30T03:01:08.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The Study Details page update reorganizes the site network by adding new locations (Santa Monica, Porto Alegre, Lyon, Gothenburg) and removing or revising others, reflecting changes in where the trial is conducted. It also adds new help sections (Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, How to Join a Study) and updates the revision to v3.6.0 on 2026-06-11.
    Difference
    0.3%
    Check dated 2026-06-15T23:26:54.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    The Gothenburg site in Sweden has its recruitment status updated from Active, not recruiting to Completed as of 2026-06-02, with the postal code corrected to 41346. The page revision to v3.5.5 records this change and updates the location data accordingly.
    Difference
    0.1%
    Check dated 2026-06-09T00:42:19.000Z thumbnail image

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.